Browsing Operational Research Courses by Authors
Childhood Tuberculosis in Dushanbe, TajikistanPirov, K; Sirojiddinova, U; Bobokhojaev, O; Zachariah, R; Lucenko, I; Mirzoev, A; Suleimenov, S; Dustmatova, Z; Rajabov, A; van den Boom, M; et al. (The World Health Organization, 2016-03)
Social Support Programme For Tuberculosis Patients in Armenia: Perceptions of Patients and DoctorsDavtyan, K; Aghabekyan, S; Davtyan, H; Margaryan, T; Zachariah, R; Acosta, C; Dadu, A; Poghosyan, V; Hayrapetyan, A (World Health Organization, 2015-12)
Tuberculosis among migrants in Bishkek, the capital of the Kyrgyz RepublicGoncharova, O; Denisiuk, O; Zachariah, R; Davtyan, K; Nabirova, D; Acosta, C; Kadyrov, A (International Union Against Tuberculosis and Lung Disease, 2017-09-21)Setting: Twenty-two first-line, two second-line and one tertiary health facility in Bishkek, the capital of Kyrgyzstan. Objectives: Among migrants, a marginalised population at risk for acquiring and transmitting tuberculosis (TB), we determined the proportion with TB among all registered TB cases. For those registered at primary-level facilities, we then reported on their demographic and clinical profiles and TB treatment outcomes. Design: This was a retrospective cohort analysis of 2012-2013 programme data. Results: Of 2153 TB patients registered in all health facilities, 969 (45%) were migrants, of whom 454 were registered in first-line facilities. Of these, 27% were cross-border migrants, 50% had infectious TB and 12% had drug-resistant TB. Treatment success was 74% for new cases and 44% for retreatment TB (the World Health Organization target is ⩾85%). Failure in new and retreatment TB patients was respectively 8% and 25%. Twenty-six individuals started on a first-line anti-tuberculosis regimen failed due to multidrug-resistant TB. Eight (25%) of 32 individuals on a retreatment TB regimen also failed. Loss to follow-up was 10% for new and 19% for retreatment TB. Conclusion: Migrants constituted almost half of all TB patients, drug resistance is prevalent and treatment outcomes unsatisfactory. Fostering inter-country collaboration and prioritising rapid TB diagnostics (Xpert® MTB/RIF) and innovative ways forward for improving treatment outcomes is urgent.